Shrugging off further declines in its diabetes business during the second quarter, Sanofi's CEO Olivier Brandicourt used the French group's half-year update to predict a turnaround in the French group's fortunes starting with a resumption of growth in the second half, fueled not by price increases but rather by its rare blood disorder and new immunology businesses.
Presenting the second-quarter performance - which saw continued declines in its troubled diabetes segment that was largely offset by its...








